Philippe Moreau

Philippe Moreau

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Philippe Moreau

Department of Hematology, University Hospital Hotel-Dieu, Nantes, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
SKShaji Kumar
Shaji Kumar
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
KAKenneth C Anderson
Kenneth C Anderson
BDBrian Durie
Brian Durie
OLOla Landgren
Ola Landgren
HAHerve Avet-Loiseau
Herve Avet-Loiseau

10 September 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
APAntonio Palumbo
Antonio Palumbo
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
SOStefania Oliva
Stefania Oliva
HLHenk M. Lokhorst
Henk M. Lokhorst
HGHartmut Goldschmidt
Hartmut Goldschmidt
PMPhilippe Moreau
Philippe Moreau
Purpose: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM).Patients and Methods: Clinical and laboratory data from 4,445 patients with NDMM enrolled onto 11 international trials were pooled together. The K-adaptive partitioning algorithm was used to define the most appropriate subgroups with homogeneous survival.Results: ISS, CA, and LDH data were simultaneously available in 3,060 of 4,445 patients. We defined the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum β2-microglobulin level < 3.5 mg/L and serum albumin level ≥ 3.5 g/dL), no high-risk CA [del(17p) and/or t(4;14) and/or t(14;16)], and normal LDH level (less than the upper limit of normal range); R-ISS III (n = 295), including ISS stage III (serum β2-microglobulin level > 5.5 mg/L) and high-risk CA or high LDH level; and R-ISS II (n = 1,894), including all the other possible combinations. At a median follow-up of 46 months, the 5-year OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS rates were 55%, 36%, and 24%, respectively.Conclusion: The R-ISS is a simple and powerful prognostic staging system, and we recommend its use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.

6 October 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
AOAlbert Oriol
Albert Oriol
HNHareth Nahi
Hareth Nahi
JSJesus San-Miguel
Jesus San-Miguel
NBNizar J. Bahlis
Nizar J. Bahlis
PMPhilippe Moreau
Philippe Moreau
Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple myeloma. In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. At a median follow-up of 13.5 months in a protocol-specified interim analysis, 169 events of disease progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% confidence interval [CI], 0.27 to 0.52; P<0.001 by stratified log-rank test). The Kaplan–Meier rate of progression-free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group. A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%, P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%, P<0.001). In the daratumumab group, 22.4% of the patients had results below the threshold for minimal residual disease (1 tumor cell per 105 white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009.)

11 August 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PMPhilippe Moreau
Philippe Moreau
AGAlfred L. Garfall
Alfred L. Garfall
NDNiels W.C.J. van de Donk
Niels W.C.J. van de Donk
HNHareth Nahi
Hareth Nahi
JSJesús F. San-Miguel
Jesús F. San-Miguel
SUSaad Z. Usmani
Saad Z. Usmani
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.

1 August 2005 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MGMorie A. Gertz
Morie A. Gertz
RCRay Comenzo
Ray Comenzo
RFRodney H. Falk
Rodney H. Falk
JFJean Paul Fermand
Jean Paul Fermand
BHBOUKE P. C. Hazenberg
BOUKE P. C. Hazenberg
GGGiles Grateau
Giles Grateau

8 January 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASA Keith Stewart
A Keith Stewart
SRS Vincent Rajkumar
S Vincent Rajkumar
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
TMTamás Masszi
Tamás Masszi
IŠIvan Špička
Ivan Špička
AIASPIRE Investigators
ASPIRE Investigators
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan–Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk–benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.)